Home/Pipeline/NA-941

NA-941

Metabolic dysfunction-associated steatohepatitis (MASH)

Phase 2AActive

Key Facts

Indication

Metabolic dysfunction-associated steatohepatitis (MASH)

Phase

Phase 2A

Status

Active

Company

Biomed

About Biomed

Biomed Industries is a late-stage private biotech with a broad and advanced pipeline targeting major neurodegenerative, metabolic, and cardiovascular diseases. Its core strategy is underpinned by a proprietary 'Unified Acceleration Platform,' a theoretical and AI-driven framework positing shared biological dysfunctions across these disease areas. The company has multiple Phase 2 and Phase 3 assets, most notably NA-931 for obesity and NA-831 for Alzheimer's, and one FDA-approved device, the MICROS Infusion System.

View full company profile

Therapeutic Areas

Neurological Diseases Metabolic Disorders Cardiovascular Diseases Rare Diseases

Other Metabolic dysfunction-associated steatohepatitis (MASH) Drugs

Drug	Company	Phase	Status
NGM831 (MK-3655)	NGM Biopharmaceuticals	Phase 2b	Active (Merck-led)
Pegozafermin (BIO89-100)	89bio	Phase 3	Active
Icosabutate	NorthSea Therapeutics	Phase 3	Active
Oxy210	MAX BioPharma	Preclinical	Active
PRO-MSH-001	ProdIgY Biotech	Discovery	Active
Undisclosed MASH Program	Syndya Therapeutics	Discovery	Active
Partnered Program	Cellarity	Pre-clinical	Active
Lanifibranor	Hepalys	Phase 1	Active (Japan development program)
IW-601	ImmuneWalk Therapeutics	Preclinical	Active
ION224 (IONIS-DGAT2Rx)	Ionis Pharmaceuticals	Phase 2b	Active
ALG-055009	Aligos Therapeutics	Phase 2	Active
CM-101	Chemomab Therapeutics	Phase 2a	Completed